---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-260425"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:10:05.256069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio reports positive CABA-201 data at ACR 2024; all 8 patients drug-free responses

## Summary
- Eight patients dosed across RESET-Myositis, -SLE, -SSc trials; all off immunosuppressants through follow-up.
- Favorable safety: no ICANS (except one prior LN case); low-grade CRS in 3/8, no tocilizumab needed.
- Complete B cell depletion by day 22; transitional naïve B cell repopulation as early as 8 weeks in first 2 patients.
- All 4 SLE patients showed clinical responses; LN patient proteinuria improved >90%. DM patient achieved major TIS response and normal muscle strength.

## SEC filing metadata
- accession: 0001193125-24-260425
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312524260425/0001193125-24-260425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312524260425/d874885d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-260425
- JSON: https://secwatch.observer/filing/0001193125-24-260425.json
- Plain text: https://secwatch.observer/filing/0001193125-24-260425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.